VC-backed Verve Therapeutics goes public
Verve Therapeutics, a biotech company focused on treating cardiovascular disease, has raised $266.7 million for its IPO after pricing its over 14 million shares at $19 per share.
17 June 2021•3 mins read
Verve Therapeutics, a biotech company focused on treating cardiovascular disease, has raised $266.7 million for its IPO after pricing its over 14 million shares at $19 per share.
